TriSalus Life Sciences (TLSI) Competitors $4.70 -0.04 (-0.84%) Closing price 03:58 PM EasternExtended Trading$4.70 0.00 (-0.11%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI vs. IRMD, CBLL, EMBC, BBNX, BVS, AVNS, KIDS, AXGN, RXST, and SMLRShould you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include iRadimed (IRMD), CeriBell (CBLL), Embecta (EMBC), Beta Bionics (BBNX), Bioventus (BVS), AVANOS MEDICAL (AVNS), OrthoPediatrics (KIDS), AxoGen (AXGN), RxSight (RXST), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry. TriSalus Life Sciences vs. Its Competitors iRadimed CeriBell Embecta Beta Bionics Bioventus AVANOS MEDICAL OrthoPediatrics AxoGen RxSight Semler Scientific iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has preferable valuation & earnings, IRMD or TLSI? iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$75.15M9.80$19.23M$1.5537.38TriSalus Life Sciences$29.43M6.04-$30.05M-$1.12-4.20 Do analysts prefer IRMD or TLSI? iRadimed presently has a consensus price target of $72.00, indicating a potential upside of 24.26%. TriSalus Life Sciences has a consensus price target of $10.75, indicating a potential upside of 128.72%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals & insiders believe in IRMD or TLSI? 92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer IRMD or TLSI? In the previous week, iRadimed and iRadimed both had 1 articles in the media. TriSalus Life Sciences' average media sentiment score of 1.89 beat iRadimed's score of 1.28 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment iRadimed Positive TriSalus Life Sciences Very Positive Is IRMD or TLSI more profitable? iRadimed has a net margin of 26.33% compared to TriSalus Life Sciences' net margin of -84.67%. iRadimed's return on equity of 23.28% beat TriSalus Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.33% 23.28% 20.59% TriSalus Life Sciences -84.67%N/A -111.63% Which has more volatility & risk, IRMD or TLSI? iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. SummaryiRadimed beats TriSalus Life Sciences on 11 of the 16 factors compared between the two stocks. Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSI vs. The Competition Export to ExcelMetricTriSalus Life SciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.47M$10.22B$5.57B$9.31BDividend YieldN/A2.09%4.23%4.03%P/E Ratio-4.1916.9728.6419.71Price / Sales6.0429.23432.34185.19Price / CashN/A22.6736.0257.93Price / Book-5.663.608.235.65Net Income-$30.05M$233.40M$3.24B$257.81M7 Day Performance-6.19%-2.51%0.05%0.37%1 Month Performance-14.70%2.05%5.65%8.66%1 Year Performance-12.96%-19.19%26.57%14.04% TriSalus Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSITriSalus Life Sciences2.9804 of 5 stars$4.70-0.8%$10.75+128.7%-9.0%$177.47M$29.43M-4.19106Positive NewsIRMDiRadimed4.7046 of 5 stars$59.24+0.4%$72.00+21.5%+25.8%$753.53M$73.24M38.22110Positive NewsCBLLCeriBell2.6065 of 5 stars$17.08-0.7%$32.14+88.2%N/A$617.27M$65.44M0.00N/AEMBCEmbecta4.7522 of 5 stars$10.32+2.9%$19.33+87.3%-25.4%$603.13M$1.08B11.472,100News CoveragePositive NewsAnalyst ForecastBBNXBeta BionicsN/A$13.56+1.2%$23.44+72.9%N/A$587.96M$65.12M0.00294Positive NewsBVSBioventus2.7115 of 5 stars$6.95+1.9%$13.75+97.8%-4.3%$570.90M$567.70M-11.391,200AVNSAVANOS MEDICAL2.8643 of 5 stars$12.16+2.8%N/A-44.8%$562.28M$687.80M-1.452,227News CoverageNegative NewsKIDSOrthoPediatrics4.2599 of 5 stars$22.00+3.6%$35.83+62.9%-33.1%$534.38M$204.73M-12.57200News CoveragePositive NewsAnalyst ForecastAXGNAxoGen2.3008 of 5 stars$11.39+0.3%$24.50+115.1%+34.8%$518.70M$187.34M-75.93450News CoveragePositive NewsAnalyst RevisionRXSTRxSight2.2271 of 5 stars$12.75+2.6%$37.90+197.3%-84.7%$518.16M$139.93M-19.03220Analyst DowngradeSMLRSemler Scientific2.5883 of 5 stars$42.71+9.7%$86.00+101.4%+21.4%$476.22M$56.29M-16.36120 Related Companies and Tools Related Companies iRadimed Competitors CeriBell Competitors Embecta Competitors Beta Bionics Competitors Bioventus Competitors AVANOS MEDICAL Competitors OrthoPediatrics Competitors AxoGen Competitors RxSight Competitors Semler Scientific Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSI Stock Alerts